{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:40:40Z","timestamp":1684543240924},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.beha.2008.08.002","type":"journal-article","created":{"date-parts":[[2008,9,18]],"date-time":"2008-09-18T16:20:37Z","timestamp":1221754837000},"page":"375-389","source":"Crossref","is-referenced-by-count":5,"title":["Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia"],"prefix":"10.1016","volume":"21","author":[{"given":"Aaron E.","family":"Foster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm K.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2008.08.002_bib1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia","volume":"333","author":"Rozman","year":"1995","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(78)91444-7","article-title":"Chronic lymphocytic leukaemia: clonal origin in a committed B-lymphocyte progenitor","volume":"2","author":"Fialkow","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2008.08.002_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.V69.3.929.929","article-title":"Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients","volume":"69","author":"Lee","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood.V78.6.1545.1545","article-title":"Presenting features and prognosis of chronic lymphocytic leukemia in younger adults","volume":"78","author":"Montserrat","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib5","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib6","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.002_bib7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.002_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bmt.1702237","article-title":"Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia","volume":"25","author":"Pavletic","year":"2000","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2008.08.002_bib9","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.002_bib10","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon","year":"1996","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2008.08.002_bib11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1080\/10428190600709721","article-title":"Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia","volume":"47","author":"Giannopoulos","year":"2006","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2008.08.002_bib12","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2004-07-2556","article-title":"Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes","volume":"105","author":"Biagi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib13","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood.V97.9.2777","article-title":"Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia","volume":"97","author":"Granziero","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib14","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.4049\/jimmunol.177.9.6548","article-title":"Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes","volume":"177","author":"Johnson","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.beha.2008.08.002_bib15","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"Gorgun","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2008.08.002_bib16","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2007-01-068932","article-title":"Cellular immune therapy for chronic lymphocytic leukemia","volume":"110","author":"Kater","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib17","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib18","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-05-0484","article-title":"Responses to human CD40 ligand\/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia","volume":"11","author":"Biagi","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2008.08.002_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.beha.2008.08.002_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nri841","article-title":"T-cell-receptor gene therapy","volume":"2","author":"Schumacher","year":"2002","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.beha.2008.08.002_bib21","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/sj.mt.6300216","article-title":"Monoclonal T-cell receptors: new reagents for cancer therapy","volume":"15","author":"Stauss","year":"2007","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.beha.2008.08.002_bib22","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","article-title":"Facilitating matched pairing and expression of TCR chains introduced into human T cells","volume":"109","author":"Kuball","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.beha.2008.08.002_bib24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ni1102-999","article-title":"Natural selection of tumor variants in the generation of \u2018tumor escape\u2019 phenotypes","volume":"3","author":"Khong","year":"2002","journal-title":"Nature Immunology"},{"key":"10.1016\/j.beha.2008.08.002_bib25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib26","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2005-01-0146","article-title":"Elimination of human leukemia cells in NOD\/SCID mice by WT1-TCR gene-transduced human T cells","volume":"106","author":"Xue","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08830189309061702","article-title":"Chimeric T cell receptor-immunoglobulin molecules: function and applications","volume":"10","author":"Hedrick","year":"1993","journal-title":"International Reviews of Immunology"},{"key":"10.1016\/j.beha.2008.08.002_bib28","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2008.08.002_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"2001","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.beha.2008.08.002_bib30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14653240310001028","article-title":"Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy","volume":"5","author":"Jensen","year":"2003","journal-title":"Cytotherapy"},{"key":"10.1016\/j.beha.2008.08.002_bib32","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2002-07-1989","article-title":"T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect","volume":"101","author":"Cooper","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000072465","article-title":"Chimeric T-cell receptors for the targeting of cancer cells","volume":"110","author":"Rossig","year":"2003","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.beha.2008.08.002_bib34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib35","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","article-title":"T-lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B-lymphocyte derived malignant cells","volume":"108","author":"Vera","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib36","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJM197605062941902","article-title":"Kappa-chain deficiency. An immunoglobulin disorder","volume":"294","author":"Zegers","year":"1976","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib37","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib38","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2008.08.002_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.beha.2008.08.002_bib40","first-page":"92a","article-title":"A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T-cells for recurrent\/refractory follicular lymphoma","volume":"110","author":"Jensen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib41","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.beha.2008.08.002_bib42","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pule","year":"2005","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.beha.2008.08.002_bib43","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2008.08.002_bib44","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Loskog","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2008.08.002_bib45","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","article-title":"Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells","volume":"115","author":"Dannull","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2008.08.002_bib46","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib47","first-page":"411","article-title":"Mouse myeloma tumor stem cells: a primary cell culture assay","volume":"46","author":"Park","year":"1971","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.beha.2008.08.002_bib48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"issue":"Suppl","key":"10.1016\/j.beha.2008.08.002_bib50","first-page":"84","article-title":"Chronic lymphocytic leukemia \u2013 an accumulative disease of immunologically incompetent lymphocytes","volume":"29","author":"Dameshek","year":"1967","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1999.17.1.399","article-title":"B-cell chronic lymphocytic leukemia: a bird of a different feather","volume":"17","author":"Caligaris-Cappio","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.002_bib52","first-page":"225","article-title":"Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation","volume":"137","author":"Pezzella","year":"1990","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.beha.2008.08.002_bib53","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V79.11.2981.2981","article-title":"Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells","volume":"79","author":"Schena","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib54","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1046\/j.1365-2141.1999.01642.x","article-title":"Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia","volume":"106","author":"Kitada","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2008.08.002_bib55","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V86.3.1090.1090","article-title":"Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells","volume":"86","author":"Lankester","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/asheducation-2006.1.273","article-title":"Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells","volume":"512","author":"Chiorazzi","year":"2006","journal-title":"Hematology \/ the Education Program of the American Society of Hematology"},{"key":"10.1016\/j.beha.2008.08.002_bib57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood.V55.2.282.282","article-title":"Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA","volume":"55","author":"Andreeff","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s001090050351","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival","volume":"77","author":"Meinhardt","year":"1999","journal-title":"Journal of Molecular Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0167-5699(99)01529-7","article-title":"Measurement of T-cell kinetics: recent methodologic advances","volume":"20","author":"Hellerstein","year":"1999","journal-title":"Immunology Today"},{"key":"10.1016\/j.beha.2008.08.002_bib60","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","article-title":"In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells","volume":"115","author":"Messmer","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2008.08.002_bib61","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2007-04-083832","article-title":"CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells","volume":"110","author":"Damle","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib62","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1182\/blood.V91.12.4694","article-title":"Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia","volume":"91","author":"Vrhovac","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/10428190400005353","article-title":"Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option","volume":"46","author":"Ringshausen","year":"2005","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2008.08.002_bib64","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.183.4.1797","article-title":"Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo","volume":"183","author":"Goodell","year":"1996","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib65","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/nm1297-1337","article-title":"Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species","volume":"3","author":"Goodell","year":"1997","journal-title":"Nature Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/stemcells.2005-0116","article-title":"A side order of stem cells: the SP phenotype","volume":"24","author":"Challen","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.beha.2008.08.002_bib67","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V98.4.1166","article-title":"A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia","volume":"98","author":"Wulf","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib68","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.0400067101","article-title":"A distinct \u2018side population\u2019 of cells with high drug efflux capacity in human tumor cells","volume":"101","author":"Hirschmann-Jax","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2008.08.002_bib69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1073\/pnas.0307618100","article-title":"Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line","volume":"101","author":"Kondo","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2008.08.002_bib70","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/hep.21227","article-title":"Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties","volume":"44","author":"Chiba","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.beha.2008.08.002_bib71","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-05-0592","article-title":"Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic","volume":"65","author":"Patrawala","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2008.08.002_bib72","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhou","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2008.08.002_bib73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2008.08.002_bib74","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2007.10.070","article-title":"Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia\/lymphoma","volume":"364","author":"Kayo","year":"2007","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.beha.2008.08.002_bib75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2008.08.002_bib76","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.beha.2008.08.002_bib77","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","article-title":"Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib78","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib79","first-page":"95","article-title":"Expression of RHAMM\/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia","volume":"29","author":"Giannopoulos","year":"2006","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.beha.2008.08.002_bib80","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1182\/blood-2005-08-3501","article-title":"The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL","volume":"107","author":"Brickner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib81","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1073\/pnas.96.15.8639","article-title":"CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells","volume":"96","author":"Bonnet","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2008.08.002_bib82","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2007-06-096313","article-title":"DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells","volume":"111","author":"Rosinski","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.002_bib83","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/sj.bjc.6603369","article-title":"The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens","volume":"95","author":"Steele","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.beha.2008.08.002_bib84","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1476-5586(03)80032-5","article-title":"Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene","volume":"5","author":"Raaphorst","year":"2003","journal-title":"Neoplasia"},{"key":"10.1016\/j.beha.2008.08.002_bib85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature01572","article-title":"Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells","volume":"423","author":"Lessard","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.beha.2008.08.002_bib86","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.beha.2008.08.002_bib87","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.177.4.925","article-title":"Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal","volume":"177","author":"Ranheim","year":"1993","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.beha.2008.08.002_bib88","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/104303401300057360","article-title":"Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes","volume":"12","author":"Takahashi","year":"2001","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.beha.2008.08.002_bib89","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1200\/JCO.2005.05.008","article-title":"Novel immune-based treatment strategies for chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.002_bib90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ijc.1616","article-title":"Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells","volume":"97","author":"Laytragoon-Lewin","year":"2002","journal-title":"International Journal of Cancer"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692608000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692608000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:21:17Z","timestamp":1684542077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692608000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1521692608000686"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2008.08.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}